Objective: To evaluate the efficacy and safety of intravenous injection of Lipo prostaglandin E1 in the treatment of coronary artery disease (CHD) combined with peripheral atherosclerotic occlusion. Methods: 100 cases of coronary heart disease with occlusion of peripheral atherosclerosis in our hospital between January 2014 to January 2017 were randomly divided into control group and experimental group. The control group received routine treatment, the experimental group received intravenous injection before Liedierlipo injection treatment, and the clinical curative effect was compared between the two groups. Results: The indexes of 6MWD, ABI and cardiac output in the experimental group were significantly higher than those in the control group (P<0.05). In the experimental group, the indexes such as Hcy, hs-CRP and so on were significantly higher than those of the control group (P<0.05). Conclusion: Patients with obstructive coronary heart disease complicated with peripheral atherosclerosis received intravenous Lipo-PGE1 treatment, showed improved heart function, efficacy and high safety.%目的:探讨静脉注射前列地尔脂微球载体注射液治疗冠心病合并闭塞性周围动脉粥样硬化的有效性和安全性.方法:本研究选择分析我院住院部2014年1月—2017年1月之间收治100例冠心病合并闭塞性周围动脉粥样硬化患者的临床资料,随机分为对照组和实验组,对照组实施常规治疗,实验组实施静脉注射前列地尔脂微球载体注射液治疗,对比两组临床疗效.结果:实验组患者治疗后6MWD、ABI和心排量等指标结果均明显高于对照组,两组比较具有明显的统计学差异(P<0.05).实验组患者治疗后代谢当量、Hcy和hs-CRP等指标结果均明显高于对照组,两组比较具有明显的统计学差异(P<0.05).结论:冠心病合并闭塞性周围动脉粥样硬化患者接受静脉注射前列地尔脂微球载体注射液治疗,有助于其心功能的改善,具有较高的有效性和安全性.
展开▼
